Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Giotakis, Aris I.a; * | Lazaris, Andreas C.b | Kataki, Agapic | Kontos, Christos K.d | Giotakis, Evangelos I.a
Affiliations: [a] First Department of Otorhinolaryngology, Hippocration Hospital, Medical University of Athens, National and Kapodistrian University of Athens, Athens, Greece | [b] Department of Pathology, Medical University of Athens, National and Kapodistrian University of Athens, Athens, Greece | [c] Laboratory of Surgical Research, 1st Department of Propaedeutic Surgery, Hippocration Hospital, Medical University of Athens, National and Kapodistrian University of Athens, Athens, Greece | [d] Department of Biochemistry and Molecular Biology, University of Athens, Athens, Greece
Correspondence: [*] Corresponding author: Aris I. Giotakis, First Department of Otorhinolaryngology, Hippocration Hospital, %****␣cbm-25-cbm181772_temp.tex␣Line␣25␣**** Medical University of Athens, National and Kapodistrian University of Athens, Vas. Sofias 114, Athens, 11527, Greece. Tel.: +302 132 088 030; E-mail: arisgiotakis@gmail.com.
Abstract: BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) constitutes the third most frequent head and neck cancer. Several tissue biomarkers have been studied for their prognostic significance in LSCC. OBJECTIVE: To investigate the prognostic significance of BCL2L12, a new member of the BCL2 family, in primary LSCC along with well-examined biomarkers such as BCL2 and BAX. METHODS: Cancerous tissue specimens of patients with primary LSCC were collected during 2005 and 2012 as pretreatment tissue biopsy. The specimens were immunohistochemically evaluated for the protein expression of BCL2L12, BCL2 and BAX. Kaplan-Meier survival curves and Cox proportional hazard regression models were performed to evaluate prognosis. RESULTS: In the study cohort of 78 patients with primary LSCC, Kaplan-Meier survival curves demonstrated that advanced-stage LSCC patients with BCL2L12-positive tumors had significantly higher OS time in comparison with advanced-stage LSCC patients with BCL2L12-negative tumors (p= 0.014). Also, advanced-stage LSCC patients with BCL2L12-positive tumors had significantly lower risk of death from LSCC compared to advanced-stage LSCC patients with BCL2L12-negative tumors (HR = 0.228, 95%CI = 0.063–0.833, p= 0.025). CONCLUSIONS:BCL2L12 protein expression could be used as a favorable prognostic tissue biomarker in patients with primary advanced-stage LSCC. On the contrary, BCL2 and BAX did not correlate with prognosis in patients with primary LSCC.
Keywords: Laryngeal neoplasms, BCL2L12, biomarkers, prognosis, survival
DOI: 10.3233/CBM-181772
Journal: Cancer Biomarkers, vol. 25, no. 2, pp. 141-149, 2019
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl